{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.07","upperLimit":"2.14","value":"2.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"}],"units":"Participants"}],"description":"PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"MEDIAN","populationDescription":"Cohort 2 ITT population","reportingStatus":"POSTED","timeFrame":"Baseline until confirmed disease progression or death, whichever occurred first (assessed at every 9 weeks for the first 12 months, thereafter every 12 weeks until data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)","title":"Progression-Free Survival (PFS) as Assessed by the IRF According to RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}